Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States

• Douglas S. Goodin ,

  Contributed equally to this work with: Douglas S. Goodin, Michael Corwin

  * E-mail: douglas.goodin@ucsf.edu

  Affiliation Department of Neurology, University of California San Francisco, San Francisco, California, United States of America

  ⨯
• Michael Corwin ,

  Contributed equally to this work with: Douglas S. Goodin, Michael Corwin

  Affiliations Slone Epidemiology Center at Boston University, Boston, Massachusetts, United States of America, Care-Safe, Boston, Massachusetts, United States of America

  ⨯
• David Kaufman,

  Affiliation Slone Epidemiology Center at Boston University, Boston, Massachusetts, United States of America

  ⨯
• Howard Golub,

  Affiliation Care-Safe, Boston, Massachusetts, United States of America

  ⨯
• Shoshana Reshef,

  Affiliation Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, United States of America

  ⨯
• Mark J. Rametta,

  Affiliation Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, United States of America

  ⨯
• Volker Knappertz,

  Affiliation Teva Pharmaceuticals, Frazer, Pennsylvania, United States of America, Department of Neurology, Heinrich Heine University, Dusseldorf, Germany

  ⨯
• Gary Cutter,

  Affiliation University of Alabama School of Public Health, Birmingham, Alabama, United States of America

  ⨯
• Dirk Pleimes

  Affiliation Myelo Therapeutics GmbH, Berlin, Germany

  ⨯